

**INVESTOR WARNING: SOURCE PRODUCTS PLACE YOUR CAPITAL AT RISK.
INVESTORS MAY NOT GET BACK THE ORIGINAL AMOUNT INVESTED**

PRESS RELEASE

(Not for release in the United States of America)

SOURCE LAUNCHES EUROPE'S FIRST BIOTECHNOLOGY ETF

London, 17 November 2014: Source, an investment firm and a leading provider of Exchange Traded Products (ETPs), is pleased to announce that it is listing the Source NASDAQ Biotech UCITS ETF on the SIX Swiss Exchange. This is the first Europe-listed ETF to track the NASDAQ Biotechnology Index.

The biotechnology sector has seen remarkable growth from a handful of companies in the 1980s to a market capitalisation of over US\$ 950 billion today. The NASDAQ Biotechnology Index reflects the performance of over 100 biotechnology and pharmaceuticals companies listed on the NASDAQ Stock Market. Constituents range from global giants with diverse portfolios to smaller companies focused on a single treatment. The Source NASDAQ Biotech UCITS ETF aims to deliver the total return of this Index.

“Since the NASDAQ Biotechnology Index launched in 1993, it has evolved into a key industry benchmark for tracking the growth and performance of this increasingly important sector,” says Rob Hughes, head of index and advisor solutions at NASDAQ. “NASDAQ has been home to some of the world’s most innovative companies in the biotech sector and we are proud of our history and partnerships in this space. We are excited to team with another innovator, Source.”

“Source is launching this product in direct response to investor demand,” adds Source CEO Ted Hood. “While there are some large, actively managed biotech funds available to Europe investors, passive options are limited. There are several ETFs, including our own, tracking the US Health Care sector, but we see many investors looking for more focused biotech exposure.”

The Source NASDAQ Biotech UCITS ETF is denominated in USD and trades on both the SIX Swiss Exchange and the London Stock Exchange. It is also registered for sale in Austria, Finland, France, Germany, Ireland, Italy (for institutional investors only), Luxembourg, the Netherlands, Norway (for institutional investors only) and Sweden.

Key product terms

Product Name:	Source NASDAQ Biotech UCITS ETF	
Benchmark index:	NASDAQ Biotechnology Index	
Base currency:	USD	
Trading currency:	USD	
ISIN:	IE00BQ70R696	
Exchange:	LSE	SIX Swiss Exchange
Bloomberg:	SBIO LN	SBIO SW
Reuters:	SBIO.L	SBIO.S
Management fee:	0.40% per annum	
Swap fee:	0.00%	
UCITS:	Yes	
Domicile:	Ireland	

Source UK Services Limited is authorised and regulated by the Financial Conduct Authority in the UK.

Important Information

The prospectus documentation describing the products, risks and related costs of Source products are available for residents of countries where such products are authorised for sale at www.source.info

The products described on www.source.info are not suitable for everyone. Investors' capital is at risk and they may get back less than they invested. Investors should not deal in these products unless they understand their nature and the extent of their exposure to risk. The value of these products can go down as well as up and can be subject to volatility due to factors such as price changes in the underlying instrument and interest rates. It is recommended that potential investors study the prospectus before investing.

ENDS

For further information:

Source

Michael John Lytle

CCTF Corporate & Financial

Adrian Flook

Tel: +44 20 3370 1102

invest@source.info

Tel: +44 20 3540 6456

aflook@ctfcomms.com

About Source

Source is an investment firm and one of Europe's leading Exchange Traded Product (ETP) providers, with approximately US\$18 billion in assets under management. Since launch in April 2009, Source has focused on delivering incremental value to European ETP investors through a combination of enhanced indices, strong partnerships, improved structuring and active trading. Its range of just under 80 products gives investors the ability to gain exposure to equities, commodities, fixed income and alternative assets, through ETF and ETC structures with deep liquidity, increased transparency and reduced counterparty risk.

Further information about Source is available at www.source.info